NCT02135484View on ClinicalTrials.gov

Radium 223 in Castrate Resistant Prostate Cancer Bone Metastases

NACompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

September 19, 2014

Primary Completion Date

November 11, 2020

Study Completion Date

November 11, 2020

Conditions
Prostate Cancer
Interventions
DRUG

Alpharadin

50 kBq (0.0014 mCi)/kg body weight, administered by slow intravenous injection over 1 minute every 4 weeks for 6 cycles (6 doses total).

Trial Locations (1)

77030

University of Texas MD Anderson Cancer Center, Houston

Sponsors

Collaborators (1)

Bayer
All Listed Sponsors
collaborator

Bayer

INDUSTRY

collaborator

Prostate Cancer Foundation

OTHER

lead

M.D. Anderson Cancer Center

OTHER